Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours

European Journal of Nuclear Medicine and Molecular Imaging
Luca FilippiOreste Bagni

Abstract

We investigated the prognostic role of (68)Ga-DOTANOC in patients affected by hepatic metastases from neuroendocrine tumours (NET) undergoing (90)Y radioembolization ((90)Y-RE). A group of 15 consecutive patients with unresectable NET liver metastases underwent (68)Ga-DOTANOC PET at baseline and 6 weeks after (90)Y-RE. Molecular response was defined as a reduction of >50% in the tumour-to-spleen ratio (ΔT/S). The patients were divided into two groups (responders with ΔT/S >50% and nonresponders with ΔT/S <50%) Patients were followed up by imaging and laboratory tests every 3 months until death or for at least 36 months following (90)Y-RE. Statistical analysis was performed to identify factors predicting overall survival (OS) and progression-free survival (PFS). A decrease in T/S ratio was seen in all patients on (68)Ga-DOTANOC PET scans performed after (90)Y-RE. Nine patients were classified as responders and six as nonresponders. The mean OS in all patients was 31.0 months. Responders had a significantly (p < 0.001) longer OS (mean 36.0 ± 2.5 months) and PFS (mean 29.7 ± 3.4 months) than nonresponders. In a multivariate analysis, none of the other examined variables including age, unilobar vs. bilobar locations, bilirubin leve...Continue Reading

References

Feb 15, 2005·The Oncologist·Johanna M Zuetenhorst, Babs G Taal
Sep 27, 2005·Best Practice & Research. Clinical Gastroenterology·Dermot O'Toole, Philippe Ruszniewski
Jan 17, 2007·European Journal of Nuclear Medicine and Molecular Imaging·P AntunesH Maecke
Apr 18, 2008·European Journal of Nuclear Medicine and Molecular Imaging·Valentina AmbrosiniStefano Fanti
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jun 3, 2009·Nature Reviews. Endocrinology·Martijn van EssenDik J Kwekkeboom
Aug 20, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Michael GabrielIrene J Virgolini
Aug 20, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Alexander R HaugMarcus Hacker
Nov 30, 2011·Nuclear Medicine Communications·Oreste BagniFrancesco Scopinaro
Dec 14, 2011·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Mohammed ShaheenPeter Metrakos
Feb 22, 2012·Journal of Medical Imaging and Radiation Oncology·Michael S HofmanRodney J Hicks
Mar 6, 2012·European Journal of Nuclear Medicine and Molecular Imaging·Valentina AmbrosiniStefano Fanti
Apr 21, 2012·International Journal of Hepatology·Ron BasuroyJohn K Ramage
Apr 25, 2012·European Journal of Nuclear Medicine and Molecular Imaging·Levent KabasakalBedii Kanmaz
Sep 19, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Samer EzziddinHojjat Ahmadzadehfar
Jun 27, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Thomas C KweeAbass Alavi
Jan 5, 2014·The Lancet Oncology·Andrea FrillingUNKNOWN Working Group on Neuroendocrine Liver Metastases
Oct 17, 2014·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·C KratochwilF L Giesel
Nov 29, 2014·Diagnostic and Interventional Radiology : Official Journal of the Turkish Society of Radiology·Ahmet PekerSadık Bilgiç
Dec 6, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Oreste BagniOrazio Schillaci
May 12, 2015·Scandinavian Journal of Gastroenterology·Andreas Kjaer, Ulrich Knigge

❮ Previous
Next ❯

Citations

Oct 5, 2017·Reviews in Endocrine & Metabolic Disorders·Louis de MestierPhilippe Ruszniewski
Jun 5, 2019·Clinical Nuclear Medicine·Luca FilippiOrazio Schillaci
Mar 12, 2020·Expert Review of Medical Devices·Luca FilippiOreste Bagni
Aug 22, 2020·Expert Review of Anticancer Therapy·Luca FilippiOreste Bagni
Nov 28, 2019·Cancers·Agostino ChiaravallotiOrazio Schillaci
Dec 11, 2020·Canadian Journal of Gastroenterology & Hepatology·Erica S TsangHagen F Kennecke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.